Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclin-dependent kinase inhibitors - Cyclacel Pharmaceuticals

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Cyclacel Pharmaceuticals

Alternative Names: 2-Anilino-4-(thiazol-5-yl)-pyrimidine - Cyclacel Pharmaceuticals; CCT-68127; CYC 11056; CYC400 series - Cyclacel Pharmaceuticals; Second-generation CDK inhibitors - Cyclacel Pharmaceuticals; Tri-substituted purines - Cyclacel Pharmaceuticals

Latest Information Update: 10 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Purines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Glomerulonephritis; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 10 Mar 2023 Discontinued - Preclinical for Neuroblastoma in United Kingdom (PO)
  • 23 Feb 2023 Discontinued - Preclinical for Acute myeloid leukaemia in United Kingdom (PO)
  • 23 Feb 2023 Discontinued - Preclinical for Cancer in United Kingdom (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top